1. Overview of the research characteristics of levofloxacin resistance of Helicobacter pylori's phenology and geology for 2012 - 2022
Main Article Content
Abstract
Currently Helicobacter pylori’s resistance to levofloxacin is a major challenge in the treatment of gastritis and peptic ulcer disease. Phenotypic and genotypic testing are basic tests that assess resistance to Helicobacter pylori levofloxacin. This review showed, in the literature, the phenotypic levofloxacin resistance rate was 38.4% (95%CI: 28.1% - 49.9%) and the genotypic levofloxacin resistance rate was 35.9% (95%CI: 28.6% - 44%) in studies published between 2012 and 2022. The difference between phenotypic and genotypic tests was not statistically significant in determining the levofloxacin resistance of Helicobacter pylori in 10/13 studies. GyrA mutations were common in codons N87K/I/T and D91N/G/Y/N and new mutations D6G/N, G208E, R140K, A92T, D97V, A88V, T239M, V172I, R130K/H, H57Y, S63P, V65I, V77A, S83A, D99V, A129T, D155N, D161N, V172I, P188S, D192N, A199V/I, V741I. GyrB mutant R484K; D481E, A584V; F438S, S429T, E463K, D481E, R579C, E684D, D435N, V437T. The current trend indicates that the phenotypic and genotypic rates of levofloxacin resistance are > 20%. It is necessary to find new antibiotic solutions to replace levofloxacin in the treatment regimen of Helicobacter pylori. In addition, genotyping can be used as an alternative to phenotypic testing in confirming Helicobacter pylori levofloxacin resistance.
Article Details
Keywords
Research overview, Helicobacter pylori, levofloxacin, phenotype, genotype
References
2. Moher DJIJS. Corrigendum to: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. International Journal of Surgery. 2010;8:336-341. 2010;8(8)
3. Beller EM, Glasziou PP, Altman DG, et al. PRISMA for abstracts: Reporting systematic reviews in journal and conference abstracts. PLoS Med. 2013;10(4):e1001419.
4. Auboire L, Sennoga C, Hyvelin J, et al. Quality assessment of the studies using the collaborative approach to meta-analysis and review of Animal Data from Experimental Studies (CAMARADES) checklist items. Plos One. 2018.
5. Dong F, Ji D, Huang R, et al. Multiple genetic analysis system-based antibiotic susceptibility testing in Helicobacter pylori and high eradication rate with phenotypic resistance-guided quadruple therapy. Medicine (Baltimore). 2015;94(47).
6. Tuan VP, Narith D, Tshibangu-Kabamba E, et al. A next-generation sequencing-based approach to identify genetic determinants of antibiotic resistance in Cambodian Helicobacter pylori clinical isolates. J Clin Med. 2019;8(6):858.
7. Palmitessa V, Monno R, Panarese A, et al. Evaluation of antibiotic resistance of Helicobacter pylori strains isolated in Bari, Southern Italy, in 2017 - 2018 by phenotypic and genotyping methods. Microb Drug Resist. 2020;26(8):909-917.
8. Tshibangu-Kabamba E, Ngoma-Kisoko PdJ, Tuan VP, et al. Next-generation sequencing of the whole bacterial genome for tracking molecular insight into the broad-spectrum antimicrobial resistance of Helicobacter pylori clinical isolates from the Democratic Republic of Congo. Microorganisms. 2020;8(6):887.
9. Mascellino MT, Oliva A, Miele MC, De Angelis M, Bruno G, Severi CJA. Secondary antibiotic resistance, correlation between genotypic and phenotypic methods and treatment in Helicobacter pylori infected patients: A retrospective study. Antibiotics (Basel). 2020;9(9):549.
10. Farzi N, Yadegar A, Sadeghi A, et al. High prevalence of antibiotic resistance in Iranian Helicobacter pylori isolates: Importance of functional and mutational analysis of resistance genes and virulence genotyping. J Clin Med. 2019;8(11):2004.
11. Lok C-H, Zhu D, Wang J, et al. Phenotype and molecular detection of clarithromycin and levofloxacin resistance in Helicobacter pylori clinical isolates in Beijing. Infect Drug Resist. 2020;13:2145.
12. Wang Y-h, Wang F-f, Gong X-l, et al. Genotype profiles of Helicobacter pylori from gastric biopsies and strains with antimicrobial-induced resistance. Therap Adv Gastroenterol. 2020;13:1756284820952596.
13. Camorlinga-Ponce M, Gómez-Delgado A, Aguilar-Zamora E, et al. Phenotypic and genotypic antibiotic resistance patterns in Helicobacter pylori strains from ethnically diverse population in Mexico. Front Cell Infect Microbiol. 2021;10:539115.
14. Cui R, Song Z, Suo B, et al. Correlation analysis among genotype resistance, phenotype resistance and eradication effect of Helicobacter pylori. Infect Drug Resist. 2021;14:1747.
15. Yang L, Zou A, Wu H, et al. Application of visual gene clip-based tailored therapy for the eradication of Helicobacter pylori. Biomed Res Int. 2021;2021:6150628.
16. Wang Y-h, Gong X-l, Liu D-w, et al. Characteristics of Helicobacter pylori heteroresistance in gastric biopsies and its clinical relevance. Front Cell Infect Microbiol. 2022:1409.
17. Zhou Y, Zhong Z, Hu S, et al. A survey of helicobacter pylori antibiotic-resistant genotypes and strain lineages by whole-genome sequencing in China. Antimicrob Agents Chemother. 2022:e02188-21.
18. Li Y, Huang Z, Shang Y, et al. Exploration of the molecular mechanisms underlying the antibiotic resistance of Helicobacter pylori: A whole-genome sequencing-based study in Southern China. Helicobacter. 2022;27(2):e12879.
19. Camargo MC, García A, Riquelme A, et al. The problem of Helicobacter pylori resistance to antibiotics: A systematic review in Latin America. Am J Gastroenterol. 2014;109(4):485.
20. Kuo Y-T, Liou J-M, El-Omar EM, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(10):707-715.
21. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: A systematic. J Gastrointestin Liver Dis. 2010;19(4):409-414.
22. Pereira FS, Bucaretchi F, Stephan C, Cordeiro RJJdp. Self-medication in children and adolescents. J Pediatr (Rio J). 2007;83:453-458.
23. Nguyễn Thị Chi. Nghiên cứu kháng kháng sinh và đánh giá hiệu quả tiệt trừ Helicobacter pylori dựa trên kháng sinh đồ. Luận văn chuyên khoa 2, Trường Đại học Y Hà Nội; 2020.
24. Miftahussurur M, Yamaoka YJM. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: An Asian perspective. Molecules. 2015;20(4):6068-6092.
25. Binh TT, Shiota S, Nguyen LT, et al. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol. 2013;47(3):233.
26. Phan Trung Nam, Trần Văn Huy, Trần Thị Như Hoa, Lê Văn An, Antonella Santona, Bianca Paglietti, Piero Cappuccinell, Salvatore Rubino. Đề kháng clarithromycin và levofloxacin của Helicobacter pylori: So sánh phương pháp đĩa khuếch tán và E-test. Tạp chí Y Dược học. 2013;3(6):63.
27. Trần Văn Khoa. Phát hiện đột biến kháng levofloxacin ở H. pylori trên bệnh nhân viêm loét dạ dày - tá tràng tại Bệnh viện Đa khoa trung tâm Tiền Giang năm 2021 bằng kỹ thuật giải trình tự gen. Tạp chí Y Dược Cần Thơ. 2021;38.
28. Trần Thiện Trung, Trần Anh Minh, Nguyễn Tuấn Anh. Nghiên cứu tỉ lệ đột biến kháng thuốc Clarithromycin và Levofloxacin của H. pylori bằng giải trình tự gen. Tạp chí Khoa học tiêu hóa Việt Nam. 2017;9(49):3074-3082.
29. Tian L, Yao Y, Yin L, et al. Direct detection of antibiotic resistance in Chinese Helicobacter pylori clinical isolates by sequencing-based approach. J Healthc Eng. 2022;2022:6436256.